EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats

Sara T Lo iD, Ronald H L Li iD, Catherine J Georges, Nghi Nguyen, Cheyenne K Chen, Claire Stuhlmann, Maureen Sigmund Oldach, Victor Noel Rivas, Samantha Fousse, Samantha P Harris, Joshua A Stern

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16727 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2023. Written by Sara T Lo and 10 co-authors. Institution: University of California Davis School of Veterinary Medicine, William R. Prichard Veterinary Medical Teaching Hospital, Davis, California, USA. Major MEDLINE topics: Rivaroxaban, Platelet Aggregation Inhibitors. Cited 13 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: EveryCat Health Foundation, National Institutes of Health T35.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Dual antithrombotic treatment (DAT) with clopidogrel and rivaroxaban sometimes is prescribed to cats with hypertrophic cardiomyopathy at risk of thromboembolism. To date, no studies have evaluated their combined effects on platelet function. Objectives/Hypothesis Evaluate the safety of DAT in healthy cats and compare, ex vivo, platelet-dependent thrombin generation and agonist-induced platelet activation and aggregation in cats treated with clopidogrel, rivaroxaban, or DAT. We hypothesized that DAT would safely modulate agonist-induced platelet activation and aggregation more effectively than single agent treatment. Animals Nine apparently healthy 1-year-old cats selected from a research colony.

Methods

Unblinded, nonrandomized ex vivo cross-over study. All cats received 7 days of rivaroxaban (0.6 ± 0.1 mg/kg PO), clopidogrel (4.7 ± 0.8 mg/kg PO), or DAT with defined washout periods between treatments. Before and after each treatment, adenosine diphosphate (ADP)- and thrombin-induced platelet P-selectin expression was evaluated using flow cytometry to assess platelet activation. Platelet-dependent thrombin generation was measured by fluorescence assay. Platelet aggregation was assessed using whole blood impedance platelet aggregometry.

Results

No cats exhibited adverse effects. Of the 3 treatments, only DAT significantly decreased the number of activated platelets (P = .002), modulated platelet activation in response to thrombin (P = .01), dampened thrombin generation potential (P = .01), and delayed maximum reaction velocity (P = .004) in thrombin generation. Like clopidogrel, DAT inhibited ADP-mediated platelet aggregation. However, rivaroxaban alone resulted in increased aggregation and activation in response to ADP. Conclusion and Clinical Importance Treatment combining clopidogrel and rivaroxaban (DAT) safely decreases platelet activation, platelet response to agonists, and thrombin generation in feline platelets more effectively than monotherapy with either clopidogrel or rivaroxaban.

Subjects

MeSH terms (MEDLINE)

RivaroxabanPlatelet Aggregation InhibitorsCatsAnimalsClopidogrelThrombinTiclopidineCross-Over StudiesAspirinBlood PlateletsPlatelet AggregationAdenosine Diphosphate

Author keywords

cardiologycardiovascularclopidogrel resistancefactor Xa inhibitorhypertrophic cardiomyopathysaddle thrombusthromboembolism

Substances

ClopidogrelRivaroxabanPlatelet Aggregation InhibitorsThrombinTiclopidineAspirinAdenosine Diphosphate

Authors and institutions

  • University of California Davis School of Veterinary Medicine, William R. Prichard Veterinary Medical Teaching Hospital, Davis, California, USA.
  • Surgical and Radiological Sciences, University of California, Davis, Davis, California, USA.
  • Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, USA.
  • Medicine and Epidemiology, University of California, Davis, Davis, California, USA.
  • Medicine and Epidemiology, University of California Davis School of Veterinary Medicine, Davis, California, USA.
  • University of California Davis School of Veterinary Medicine - VME, UC Davis 2108 Tupper Hall, One Shields Avenue, Davis, California 95616-5270, USA.

ORCID profiles: Sara T Lo, Ronald H L Li

Funding

  • EveryCat Health Foundation
  • National Institutes of Health T35

Cite

APA

Lo, S. T., Li, R. H. L., Georges, C. J., Nguyen, N., Chen, C. K., Stuhlmann, C., Oldach, M. S., Rivas, V. N., Fousse, S., Harris, S. P., & Stern, J. A. (2023). Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16727

Vancouver

Lo ST, Li RHL, Georges CJ, Nguyen N, Chen CK, Stuhlmann C, et al. Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16727

BibTeX
@article{Lo2023,
  author = {Lo, Sara T and Li, Ronald H L and Georges, Catherine J and Nguyen, Nghi and Chen, Cheyenne K and Stuhlmann, Claire and Oldach, Maureen Sigmund and Rivas, Victor Noel and Fousse, Samantha and Harris, Samantha P and Stern, Joshua A},
  title = {Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16727}
}
Start for free →